Drug intelligence / Profile preview

ErNPs@POL6326

Development stage: Preclinical
Lead developer: Chinese Academy of Sciences
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Subcutaneous

Overview

ErNPs@POL6326 is a CXCR4-targeted near-infrared-IIb (NIR-IIb) fluorescent rare-earth nanoprobe developed for the in vivo real-time detection of sentinel lymph node (SLN) metastasis in breast cancer. The probe consists of erbium-doped rare-earth nanoparticles (ErNPs) with bright down-conversion fluorescence at 1,556 nm, covalently conjugated with the CXCR4 peptide antagonist balixafortide (POL6326). Following subcutaneous administration, ErNPs@POL6326 drains into the SLNs and specifically targets metastatic breast cancer cells via CXCR4-mediated endocytosis, enabling noninvasive, real-time, and dynamic evaluation of lymph node metastasis status.

Other names: NaErF4@NaYF4@PAA@Balixafortide

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on ErNPs@POL6326.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ErNPs@POL6326.

Explore the full profile